Brain-derived neurotrophic factor (BDNF) plays an important role in the treatment of schizophrenia with electroconvulsive therapy (ECT) or antipsychotic (AP) drugs. However, it is unclear whether BDNF is a mediator; we therefore assumed that baseline BDNF level can mediate the efficacy of ECT-AP treatment. A total of 160 patients with schizophrenia were examined; 80 received AP monotherapy and the other 80 were treated with a combination of ECT and AP. BDNF concentration was measured by enzyme-linked immunosorbent assay using the Emax Immunoassay System kit (Promega, Madison, WI, USA) according to the manufacturer's instructions.Log-linear analyses were used to examine the relationship between demographic characteristics, BDNF level, and clinical features and response status. The baseline BDNF levels and BDNF level increment were the best predictors of clinical outcome (OR1 = 3.358, P = 0.000; OR2 = 3.243, P = 0.000).The higher baseline BDNF levels and greater BDNF level increment were found to be associated with good outcome.

中文翻译：

---

神经营养因子的变化对于预测精神分裂症的电休克治疗结果至关重要

脑源性神经营养因子 (BDNF) 在电休克疗法 (ECT) 或抗精神病 (AP) 药物治疗精神分裂症中发挥重要作用。然而，目前尚不清楚 BDNF 是否是中介体；因此，我们假设基线 BDNF 水平可以调节 ECT-AP 治疗的疗效。共检查了 160 名精神分裂症患者；80 人接受 AP 单药治疗，另外 80 人接受 ECT 和 AP 联合治疗。根据制造商的说明，使用 Emax 免疫分析系统试剂盒（Promega，麦迪逊，威斯康星州，美国）通过酶联免疫吸附测定法测量 BDNF 浓度。对数线性分析用于检查人口学特征、BDNF 水平和临床之间的关系功能和响应状态。